RxDoctor Payments Data

Nathan Riddell, MD

Cardiovascular Disease · Worcester, MANPI 1245670983

Payments from drug & device makers

$6,655in general payments, 2019–2025

Across 92 payments — averaging $72.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$3K
  • Penumbra, Inc.$1K
  • Medtronic$1K
  • Boston Scientific$406
  • Amgen$209
  • Novartis$200
  • plus $1K from 19 others

What the payments were for

  • Speaking & faculty fees$2,75041%
  • Travel & lodging$1,47322%
  • Food & beverage$2,43337%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,655 in reported general payments places this provider in the 65th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$193,357
Medicare patients
1,464
Services billed
2,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$79,636
XareltoRivaroxaban20$26,621
FarxigaDapagliflozin Propanediol28$22,977
BrilintaTicagrelor12$10,289
Metoprolol Succinate181$3,121
Atorvastatin Calcium171$2,945
ClopidogrelClopidogrel Bisulfate113$1,916
Spironolactone100$1,235
Prasugrel Hcl15$956
Lisinopril74$631
Losartan Potassium47$625
Warfarin Sodium30$586
Valsartan12$541
Torsemide24$479
Furosemide75$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$79,63664 claims
AstraZenecaFarxiga, Brilinta$116$33,26640 claims
Johnson & JohnsonXarelto$115$26,62120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →